Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › imatinib

imatinib

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of imatinib

68 trials tracked of imatinib: 14 in phase 3 or 4 and 3 with published results. The most-cited published study has 491 citations.

68Trials tracked
14Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 14 Phase 2 53 Other / NA 1
  1. Phase 3 A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed · 491 cited
  2. Phase 3 A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Completed · 490 cited
  3. Phase 3 Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) Completed · 97 cited
  4. Phase 3 A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase Completed
  5. Phase 3 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants Completed
  6. Phase 3 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed
Show 44 more trials
  1. Phase 3 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed
  2. Phase 3 Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients Completed
  3. Phase 3 Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Completed
  4. Phase 3 Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension Completed
  5. Phase 3 Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib Completed
  6. Phase 3 A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed
  7. Phase 3 Imatinib (QTI571) in Pulmonary Arterial Hypertension Completed
  8. Phase 3 Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT Completed
  9. Phase 2 Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia Completed
  10. Phase 2 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed
  11. Phase 2 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Completed
  12. Phase 2 Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma Completed
  13. Phase 2 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed
  14. Phase 2 An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis Completed
  15. Phase 2 Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer Completed
  16. Phase 2 ALL Adult Consortium Trial: Adult ALL Trial Completed
  17. Phase 2 Treatment of Older Adults With Acute Lymphoblastic Leukemia Completed
  18. Phase 2 Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Completed
  19. Phase 2 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) Completed
  20. Phase 2 Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer Completed
  21. Phase 2 Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib Completed
  22. Phase 2 A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis Completed
  23. Phase 2 Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Completed
  24. Phase 2 Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia Completed
  25. Phase 2 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed
  26. Phase 2 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Completed
  27. Phase 2 Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Completed
  28. Phase 2 S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer Completed
  29. Phase 2 A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene Completed
  30. Phase 2 Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers Completed
  31. Phase 2 Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed
  32. Phase 2 Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma Completed
  33. Phase 2 PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study Completed
  34. Phase 2 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor Completed
  35. Phase 2 Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed
  36. Phase 2 BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Completed
  37. Phase 2 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Completed
  38. Phase 2 Gleevec Study for Patients With Ovarian Cancer Completed
  39. Phase 2 Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. Completed
  40. Phase 2 A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin Completed
  41. Phase 2 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  42. Phase 2 Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia Completed
  43. Phase 2 Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer Completed
  44. Phase 2 Imatinib Mesylate in Treating Patients With Recurrent Meningioma Completed

Showing the 50 most-cited and recently-updated of 68 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Hematology Sys. Review
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
Frontiers May 15, 2026
Genetic variants in ABCB1 and ABCG2 raise imatinib trough levels in CML patients
Hematology Meta-analysis
Genetic variants in ABCB1 and ABCG2 raise imatinib trough levels in CML patients Genes affect imatinib drug levels in chronic myeloid leukemia patients
A meta-analysis shows specific ABCB1 and ABCG2 polymorphisms significantly increase imatinib plasma trough concentrations, supporting pharma…
Certain gene variants can raise imatinib levels in leukemia patients. This may help doctors personalize treatment for better results.
May 4, 2026
Adjuvant Imatinib Beyond 3 Years in High-Risk GIST: 5-Year Relapse-Free Survival Outcomes
Oncology Cohort
Adjuvant Imatinib Beyond 3 Years in High-Risk GIST: 5-Year Relapse-Free Survival Outcomes Extending Imatinib beyond 3 years did not improve survival for high-risk GIST patients
This retrospective cohort study evaluated adjuvant imatinib duration in 75 patients with high-risk GIST after radical surgery.
A look at past data shows taking Imatinib longer than three years did not help high-risk GIST patients live longer or stay cancer-free.
Frontiers Apr 27, 2026
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04
Hematology Phase II
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04 Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Apr 8, 2026
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response
Hematology Cohort
Imatinib reduces TNF-α levels in CML patients; persistent levels correlate with poor response Imatinib treatment reduces inflammatory marker in CML patients in small study
A prospective observational cohort of 40 chronic-phase CML patients in India found imatinib significantly reduced serum TNF-α levels from 25…
Dropping inflammation markers in CML patients on imatinib treatment may help doctors predict who will respond well to the drug.
Frontiers Apr 1, 2026